open access

Vol 51, No 2 (2020)
ORIGINAL RESEARCH ARTICLE
Published online: 2020-06-01
Submitted: 2019-11-27
Get Citation

Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Jan Styczynski, Gloria Tridello, Lidia Gil, Per Ljungman, Malgorzata Mikulska, Steffie van der Werf, Nina Simone Knelange, Diana Averbuch, Gerard Socié, Hendrik Veelken, Jean-Hugues Dalle, Mahmoud Aljurf, Alphan Kupesiz, Yves Bertrand, Abdelghani Tbakhi, Boris Afanasyev, Bruno Lioure, Hélène Labussière-Wallet, Xavier Poiré, Johan Maertens, Eefke Petersen, Patrice Chevallier, Noel Milpied, John A. Snowden, Ibrahim Yakoub-Agha, Jan Cornelissen, Nicolaas Schaap, Carlo Dufour, Regis Peffault de Latour, Arjan Lankester, Simone Cesaro
DOI: 10.2478/ahp-2020-0015
·
Acta Haematol Pol 2020;51(2):73-80.

open access

Vol 51, No 2 (2020)
ORIGINAL RESEARCH ARTICLE
Published online: 2020-06-01
Submitted: 2019-11-27

Abstract

Background

In patients with acute leukemia, lymphoma and chronic malignancies, donor and/or recipient Epstein-Barr virus (EBV) seropositive status increases the risk of development of chronic graft-versus-host disease (cGVHD) after allo-hematopoietic cell transplantation (allo-HCT), while it has no influence on other transplant outcomes. No data are available on the impact of EBV serostatus on transplant outcomes in patients with nonmalignant hematological disorders.

Objective

We analyzed the influence of the recipient's (R) and donor's (D) EBV serostatus on transplant outcomes (overall survival (OS); relapse-free survival (RFS); relapse incidence (RI); nonrelapse mortality (NRM); acute graft-versus-host disease (aGVHD); cGVHD) in patients with nonmalignant hematological disorders undergoing allo-HCT.

Patients and Methods

A total of 2,355 allo-HCTs performed between 1997 and 2016 for acquired bone marrow failure or hemoglobinopathies were included in this retrospective Registry megafile Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (IDWP-EBMT) study.

Results

Array

Conclusions

Allo-HCT from EBV-seropositive versus EBV-seronegative donors are at 31% higher risk of cGVHD in patients with nonmalignant hematological disorders undergoing allo-HCT; however this difference is nonsignificant in multivariate analysis.

Abstract

Background

In patients with acute leukemia, lymphoma and chronic malignancies, donor and/or recipient Epstein-Barr virus (EBV) seropositive status increases the risk of development of chronic graft-versus-host disease (cGVHD) after allo-hematopoietic cell transplantation (allo-HCT), while it has no influence on other transplant outcomes. No data are available on the impact of EBV serostatus on transplant outcomes in patients with nonmalignant hematological disorders.

Objective

We analyzed the influence of the recipient's (R) and donor's (D) EBV serostatus on transplant outcomes (overall survival (OS); relapse-free survival (RFS); relapse incidence (RI); nonrelapse mortality (NRM); acute graft-versus-host disease (aGVHD); cGVHD) in patients with nonmalignant hematological disorders undergoing allo-HCT.

Patients and Methods

A total of 2,355 allo-HCTs performed between 1997 and 2016 for acquired bone marrow failure or hemoglobinopathies were included in this retrospective Registry megafile Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (IDWP-EBMT) study.

Results

Array

Conclusions

Allo-HCT from EBV-seropositive versus EBV-seronegative donors are at 31% higher risk of cGVHD in patients with nonmalignant hematological disorders undergoing allo-HCT; however this difference is nonsignificant in multivariate analysis.

Get Citation

Keywords

hematopoietic cell transplant; graft-versus-host disease; Epstein-Barr virus; overall survival

About this article
Title

Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Journal

Acta Haematologica Polonica

Issue

Vol 51, No 2 (2020)

Pages

73-80

Published online

2020-06-01

DOI

10.2478/ahp-2020-0015

Bibliographic record

Acta Haematol Pol 2020;51(2):73-80.

Keywords

hematopoietic cell transplant
graft-versus-host disease
Epstein-Barr virus
overall survival

Authors

Jan Styczynski
Gloria Tridello
Lidia Gil
Per Ljungman
Malgorzata Mikulska
Steffie van der Werf
Nina Simone Knelange
Diana Averbuch
Gerard Socié
Hendrik Veelken
Jean-Hugues Dalle
Mahmoud Aljurf
Alphan Kupesiz
Yves Bertrand
Abdelghani Tbakhi
Boris Afanasyev
Bruno Lioure
Hélène Labussière-Wallet
Xavier Poiré
Johan Maertens
Eefke Petersen
Patrice Chevallier
Noel Milpied
John A. Snowden
Ibrahim Yakoub-Agha
Jan Cornelissen
Nicolaas Schaap
Carlo Dufour
Regis Peffault de Latour
Arjan Lankester
Simone Cesaro

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl